Competitor Analysis: Human Growth Hormone (hGH)
Product description
The Competitive Intelligence Report Human Growth Hormone (hGH) as of April 2013 provides a competitor analysis in the development pipeline of biosimilar versions of somatropin and next generation biobetter/biosuperior hGH products for treatment of growth hormone deficiency (GHD) in childrens and adults and related diseases. 2012 global sales data of branded hGH products in regulated marktes are provided. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently marketed hGH products and active projects in research and development of novel hGH products. In addition, the report lists company-specific R&D pipelines of hGH products and projects Competitor projects are listed in a tabular format providing Information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The Competitive Intelligence Report Human Growth Hormone (hGH) as of April 2013 provides a competitor analysis in the development pipeline of biosimilar versions of somatropin and next generation biobetter/biosuperior hGH products for treatment of growth hormone deficiency (GHD) in childrens and adults and related diseases. 2012 global sales data of branded hGH products in regulated marktes are provided. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently marketed hGH products and active projects in research and development of novel hGH products. In addition, the report lists company-specific R&D pipelines of hGH products and projects Competitor projects are listed in a tabular format providing Information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Territory,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
- 2012 Sales of Branded Somatropin Products in Regulated Markets
- 2012 Sales of Selected Somatropin Products in Non-Regulated Markets
- 1st Generation: Somatropin in Regulated Markets
- 1st Generation: Biosimilar Somatropin in Regulated Markets
- 2nd Generation: Injectable Somatropin in Slow-release Formulation in Regulated Markets
- 2nd Generation: Injectable Long-acting Somatropin in Regulated Markets
- 2nd Generation: Injection-Free Somatropin in Regulated Markets
- 1st Generation: Somatropin Products in Non-Regulated Markets
- 2nd Generation: Injectable Long-Acting Somatropin Products in Non-Regulated Markets
- Non-Medical, Legal Uses of Somatropin
- Corporate hGH R&D Pipelines
